125 results about "Immune Stimulation" patented technology

The invention is applicable to the technical field of medical instruments, and provides a subskull epidural micro-invasive flexible brain-computer interface electrode, which comprises a plurality of electrode branches, each electrode branch comprises a linear flexible main body, and the flexible main body comprises a micro power supply circuit and a signal circuit which are solidified. A plurality of electrode units are arranged on the micro power supply circuit and the signal circuit at intervals, and the electrode units are electrically connected with the micro power supply circuit and the signal circuit. The brain-computer interface electrode is in a flexible line type, can be implanted into the middle artery of the meninx, does not need craniotomy, is a micro-invasive brain-computer interface, has data monitoring accuracy close to that of an invasive brain-computer interface, does not need to worry about inflammatory response, immunostimulation, biocompatibility, brain tissue damage and other adverse factors after long-term implantation, and is suitable for popularization and application. And the thrombogenic risk of a vein stent brain-computer interface does not exist.

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The invention relates to the technical field of biological pharmacy, and discloses a QS-21 saponin adjuvant as well as a preparation method and application thereof, the adjuvant is a composite liposome and comprises a liposome skeleton composed of distearoyl phosphatidylcholine and cholesterol, and QS-21 saponin, monophosphoryl lipid A and a local anesthetic are jointly entrapped in the liposome skeleton. The problem that high reactogenicity and immunogenicity of potent adjuvants are difficult to consider at the same time is solved, the immunostimulation component and the pain inhibition component are jointly entrapped in the same nano-carrier, collaborative delivery in injection local is achieved, and therefore pain and swelling caused by the adjuvants are accurately inhibited. The co-entrapment structure avoids the potential inhibition effect of the free anesthetic on the immune system, the potent body fluid and cellular immune enhancement activity of the adjuvant is completely reserved, and a new technical scheme is provided for developing vaccines with high safety and strong immune efficacy.

Disclosed herein are compositions and methods of use thereof for the prevention of mastitis in dairy cattle. The compositions and methods can have immunostimulant effectiveness against mastitis-causing bacteria. In particular embodiments, the methods include preventing mastitis infection by intramammary infusion of a disclosed composition at dry-off.

The invention relates to the technical field of medicinal chemistry, and provides a TLR4 agonist, application thereof and a vaccine composition. The TLR4 agonist is a compound with a structure as shown in a formula 1 or a pharmaceutically acceptable salt thereof, the compound is glucosamine aminoalkyl 4-phosphate series molecules derived from MPL-12 structure modification, and the series molecules have enhanced immunostimulatory activity and selective immune response induction capability.

This disclosure relates to polyethylene glycol (PEG) -functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G / P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

The present invention relates to a compound represented by formula (I) or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of a compound represented by formula (I), TIFF2026503201000033.tif3981X1, X2 and X3 are each independently an optionally substituted C1-C 15 alkylene, and R and R are each independently an optionally substituted C-C 40 Alkyl, optionally substituted C-C 40 Heteroalkyl, optionally substituted C-C 40 Alkenyl, optionally substituted C-C 40 Heteroalkenyl, optionally substituted C-C 40 Alkynyl or optionally substituted C-C 40 The present invention provides a compound comprising heteroalkynyl, wherein R3, R4, R5, and R6 are each independently H, halogen, or optionally substituted C1-C3 alkyl, and the substituents are independently selected from halogen, -OH, -SH, -NH2, -NO2, cyano, and C1-C3 alkyl, which has the advantages of low cytotoxicity, strong delivery ability, and strong immunostimulatory effect.

The invention relates to the technical field of biological medicine, and discloses a nano composite adjuvant as well as a preparation method and application thereof. The composite adjuvant mainly comprises a TLR9 agonist CpG ODN, a nanoscale liposome, a cationic lipid DOTAP and a high-efficiency immunologic stimulant QS-21, several adjuvant components are prepared into the stable and uniform nanoscale liposome by adopting a microfluidic synthesis method, CpG is wrapped inside the nanoscale liposome, QS-21 is adsorbed outside the nanoscale liposome, a stable immunologic stimulation compound is formed, and the immunologic stimulant can be used for immunologic detection of the TLR9 agonist CpG ODN, the cationic lipid DOTAP and the high-efficiency immunologic stimulant QS-21. All the components have a remarkable synergistic effect, and are matched with corresponding antigens to generate strong and lasting cellular immune and humoral immune responses.

Disclosed is a method for evaluating the immunostimulatory capacity of a target substance, the method including a contacting step in which a human plasmacytoid dendritic cell line is cultured in the presence of the target substance, wherein the human plasmacytoid dendritic cell line is the CAL-1 cell line (accession number FERM BP-10914), and the CAL-1 cells are in a starvation state during at least part of the contacting step.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

This invention relates to the field of biopharmaceutical technology, disclosing a QS-21 saponin adjuvant, its preparation method, and its applications. The adjuvant is a composite liposome comprising a liposome backbone composed of distearate phosphatidylcholine and cholesterol, with QS-21 saponin, monophosphatidyllipid A, and a local anesthetic co-encapsulated therein. This invention solves the common problem of high reactivity and immunogenicity in potent adjuvants by co-encapsulating immunostimulatory and analgesic components on the same nanocarrier, achieving synergistic delivery at the injection site, thereby precisely inhibiting adjuvant-induced pain and swelling. This co-encapsulation structure avoids the potential inhibitory effect of free anesthetics on the immune system, fully preserving the adjuvant's potent humoral and cellular immune-enhancing activity. This invention provides a new technical solution for developing vaccines with both high safety and strong immunogenicity.

Contemplated treatments and methods produce substantially increased quantities of memory T-cells and a persistent immune response by subcutaneous and / or subdermal co-administration of (1) a vector comprising a recombinant nucleic acid that encodes a cancer associated epitope, a cancer specific epitope, and / or a neoepitope, (2) an immune stimulating cytokine, and (3) a checkpoint inhibitor. Most typically, the co-administration is performed at substantially the same location, preferably within 1-21 days from each other, and the vector is an adenoviral expression vector, for example, included in a viral particle such as an AdV5 virus with a deletion of the E2b gene.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and / or optionally one or more additional anti-cancer agents.

Provided herein are immune-stimulating anti-HBsAg antibody conjugates, such as a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of use thereof for treating, preventing, or alleviating one or more symptoms of HBV infection.

The present invention relates to compositions comprising an inactivated Mycobacterium or an immunogenic fraction thereof, for use in the prevention of an infection in a subject, wherein the infection is selected from the group consisting of a protozoan parasitic infection and a bacterial infection, with the proviso that the infection is not caused by a Mycobacterium.

Provided herein are immune stimulating anti-HBsAg antibody conjugates, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an HBV infection.

The invention provides a nucleic acid aptamer, and the nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID No: 1, or a sequence having 80% or more of identity with the nucleotide sequence. The nucleic acid aptamer successfully screened out in the invention has good affinity and specificity with CD40, and the binding capacity of the nucleic acid aptamer can be comparable with that of an antibody. In the functional level, the nucleic acid aptamer can be effectively combined with DC2.4 cells expressing CD40 and up-regulate the expression of related genes; the compound also shows remarkable immunostimulatory activity in an animal model, and shows a synergistic effect when being combined with an immunostimulant. The invention provides an important basis for subsequent development and transformation application of the CD40 nucleic acid aptamer, and also provides a new candidate tool and technical support for drug research and development based on a CD40 target spot.

A system and corresponding method are provided for identifying a subpopulation of cancer patients who are immunotherapy respondents. An effective method of assessing neoantigen presentation is provided. A vaccine composition is also provided. The vaccine composition is prepared by feeding data for a subject with a type of cancer into a predictive model and scoring neoantigens that occur in data for the subject for one or more parameters. One or more vaccine compositions to be administered to the subject are prepared for one or more somatic mutations for one or more neoantigens that satisfy an immune stimulation threshold.

The present invention relates to a composition for enhancing immunity, containing Cheongwi-san as an active ingredient. The Cheongwi-san of the present invention is a mixed herbal medicine extract consisting of Cimicifuga heracleifolia, Moutan Radicis Cortex, Angelica gigas, Coptis Rhizome, and fresh root of Rehmannia glutinosa. The Cheongwi-san of the present invention has excellent effects of increasing the activity of NK cells, increasing the production amounts of IFN-γ and TNF-α, and reducing the survival rate of cancer cells, and has the effect of inhibiting influenza virus infection, and thus can be effectively used as a health functional food for enhancing immunity, a feed additive for animals for enhancing immunity, or a pharmaceutical product for preventing and treating diseases caused by decreased immunity.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The application relates to the field of nanobiomedicine, and particularly relates to an engineered vesicle and a preparation method and application thereof. The engineered vesicle comprises a nano-vesicle and a calcium phosphate mineralized film coated on the surface of the nano-vesicle, and the nano-vesicle contains p53 protein. The p53 protein contained in the engineered vesicle promotes tumor aging to inhibit proliferation and metastasis, and the aged tumor cells can enhance the immune response against tumors at the tumor site, and the outer calcium phosphate mineralized film coating enables the nano-vesicle particles to effectively reduce the risk of severe inflammation in the body, to be gathered at the tumor site by the EPR effect, and under the acidic tumor microenvironment, the pH-sensitive calcium phosphate mineralized film is broken to expose the vesicle with certain immune stimulating capacity, which synergistically activates the immune response against tumors. The engineered vesicle has wide application prospects, and also lays a foundation for the design and development of a corresponding drug delivery system.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The invention belongs to the technical field of medicines, and particularly relates to a compound for targeted CSDE1 phase separation and application of the compound in virus resistance. According to the invention, it is found for the first time that the compound 5350-0763 is directly combined with the CSDE1 protein to inhibit the interaction between the compound 5350-0763 and RNA, so that the formation of a CSDE1-RNA aggregate is destroyed. By destroying CSDE1 agglomerates and releasing isolated immune stimulation RNA, RIG-I and other sensors can effectively recognize, so that virus immune escape is relieved, and host innate immune response is restarted. Meanwhile, co-phase separation of CSDE1 and SARS-CoV-2 nucleocapsid protein can be destroyed, and the immune antagonism ability of the virus is weakened. According to the invention, a new medicinal application is developed for the compound 5350-0763, and an experimental foundation is laid and a new view is provided for developing efficient and specific anti-RNA virus medicines, so that the compound 5350-0763 has important clinical significance and social benefits.

Disclosed are means, methods, and compositions of matter useful for treatment of oncological indications through stimulation of protective anti-cancer immunity. In one embodiment the invention discloses the unexpected effect of astrocytes to augment immune stimulating activities of dendritic cells. In one embodiment dendritic cells are pulsed with tumor lysates and subsequently co-cultured with astrocytes in the presence of toll-like receptor agonists.

A method for producing a polysaccharide includes extracting from broccoli with hot water to obtain an extract, purifying the extract by a chromatography column, and hydrolyzing the purified extract with oxalic acid. The chromatography column can be a DEAE cellulose chromatography column. The polysaccharide produced can have innate immune stimulating activity.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The invention provides application of pentenedioic acid (GC) in enhancing the anti-tumor effect of T cells through metabolic reprogramming, and belongs to the technical field of biological medicine. It is found that in the tumor development process, GC is supplemented in an exogenous mode, tumor growth can be rapidly inhibited, and the anti-tumor effect depends on a TME regulation and control mechanism. Through GC treatment, the TME immune landscape can be significantly remodeled; gC treatment not only can enhance the effector function of the CD8 + T cells, but also can delay the depletion process of the CD8 + T cells; and the infiltration CD8 + T cells in the tumor of the GC treatment group are obviously increased. Particularly, after the CD8-resistant antibody is used for removing mouse CD8 + T cells, the anti-tumor effect of GC completely disappears, and it is confirmed that the tumor inhibition effect depends on the CD8 + T cells. Therefore, the invention proves that the lysine catabolic metabolite GC, as an immunostimulatory metabolite, can shape the immune activated TME by reactivating the functions of tumor infiltrating CD8 + T cells.